These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20549577)

  • 21. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost implications of a polypill for primary prevention in the TIPS-3 trial.
    Lamy A; Tong W; Joseph P; Gao P; Pais P; Lopez-Jaramillo P; Walli-Attaei M; Dans AL; Xavier D; Talukder S; Santoso A; Gamra H; Yusuf S
    Eur Heart J Qual Care Clin Outcomes; 2022 Nov; 8(8):899-908. PubMed ID: 34962984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
    Webster R; Rodgers A
    Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach.
    Wald DS; Wald NJ
    J Eval Clin Pract; 2012 Jun; 18(3):612-5. PubMed ID: 21276141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
    Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
    J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
    Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
    BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
    Bosch JJ; O'Donnell MJ; Gao P; Joseph P; Pais P; Xavier D; Dans A; Lopez Jaramillo P; Yusuf S
    JAMA Neurol; 2023 Mar; 80(3):251-259. PubMed ID: 36716007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
    Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
    ; Yusuf S; Attaran A; Bosch J; Joseph P; Lonn E; McCready T; Mente A; Nieuwlaat R; Pais P; Rodgers A; Schwalm JD; Smith R; Teo K; Xavier D
    Eur Heart J; 2014 Feb; 35(6):353-64. PubMed ID: 24288261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
    González-Juanatey JR; Tamargo J; Torres F; Weisser B; Oudovenko N
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):51-58. PubMed ID: 31983653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.